Last reviewed · How we verify

NCT04160832

Prevalence and Spectrum of Cancer Susceptibility Among Patients with Advanced Colorectal Polyps

Completed Last updated 15 January 2025
What this trial tests

trial testing Multi-Cancer Cancer Panel in Colorectal Neoplasm in 200 participants. Completed in 30 August 2024.

Timeline
24 October 2019
Primary endpoint
30 August 2024
30 August 2024

Quick facts

Lead sponsorUniversity of Colorado, Denver
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date24 October 2019
Primary completion30 August 2024
Estimated completion30 August 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 89, any sex, with Colorectal Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is being conducted to determine the prevalence and risk factors for germline cancer susceptibility genetic mutations among patients with advanced colorectal polyps.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Colorectal Neoplasm

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04160832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing